human bioavailability is unknown Subcutaneous injection Human subcutaneous bioavailability and pharmacokinetics are unknown Factor Convenience Oral capsules No mixing or syringe math Subcutaneous injection Requires reconstitution, sterile supplies, and injection-site planning Factor Evidence limits Oral capsules No controlled human dose, benefit, or safety trial Subcutaneous injection No controlled human dose, benefit, or safety trial Factor Can the amounts be treated as equal
| Bierl, C., et al
What the Future Holds for Cagrilintide Ongoing studies are assessing long-term cardiovascular outcomes , weight loss durability, and real-world adherence
People with autoimmune disorders (especially thyroid disorders such as Hashimotos thyroiditis and Graves disease) Type 1 diabetes, vitiligo, lupus, Addisons disease, ulcerative colitis, infertility, acquired agammaglobulinemia, or a family history of these disorders
By contrast, in an updated meta-analysis of 86 published studies of the association of the polymorphism with CHD, the excess CHD risk in TT homozygotes compared to CC homozygotes was 15%